Metis TechBio Debuts in Hong Kong After HK$2.1 Billion IPO as AI Drug Stocks Surge 167%
Updated
Updated · Bloomberg · May 12
Metis TechBio Debuts in Hong Kong After HK$2.1 Billion IPO as AI Drug Stocks Surge 167%
2 articles · Updated · Bloomberg · May 12
HK$2.1 billion raised in Metis TechBio’s IPO sets up the AI-focused biotech for its Hong Kong trading debut after shares were priced at HK$10.50 each.
Metis develops and formulates drugs using artificial intelligence, placing it in a biotech niche drawing stronger investor demand in Hong Kong listings.
A 167% surge in Insilico Medicine since its late-December debut has helped fuel enthusiasm for AI drug-discovery names and supported the current deal wave.
That momentum is extending through the pipeline, with Earendil Labs also weighing a Hong Kong listing that could raise as much as $500 million.
With a 357% grey market surge, is Metis TechBio's debut a sign of true value or a dangerous market bubble?
AI promises to slash drug discovery time, but can it break the expensive bottleneck of human clinical trials?